The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).
 
Raphael Bueno
Honoraria - AstraZeneca
Research Funding - Genentech (Inst); HTG Molecular Diagnostics (Inst); Myriad Genetics (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - pending
Travel, Accommodations, Expenses - AstraZeneca
 
Ritu R. Gill
No Relationships to Disclose
 
Patrick H. Lizotte
No Relationships to Disclose
 
Kam Sprott
Employment - Verastem
 
David Michael Jackman
Consulting or Advisory Role - Bayer; Celgene; CVS Caremark; Genentech; Lilly
 
Julianne Barlow
No Relationships to Disclose
 
Sristi Sharma
No Relationships to Disclose
 
Beow Y. Yeap
No Relationships to Disclose
 
Lucian R. Chirieac
No Relationships to Disclose
 
Abraham Lebenthal
No Relationships to Disclose
 
Megan Cavanaugh
No Relationships to Disclose
 
Amanda J Rode
No Relationships to Disclose
 
Paul Kirschmeier
No Relationships to Disclose
 
David J. Kwiatkowski
Consulting or Advisory Role - AstraZeneca
Research Funding - AADi
 
Kwok-Kin Wong
No Relationships to Disclose
 
William G. Richards
No Relationships to Disclose
 
David T. Weaver
Employment - Verastem
Stock and Other Ownership Interests - Verastem